Bio Essence Corporation Reports Revenue Surge to $1.3 Million and Net Income of $475,450 for First Half of 2026

Bio Essence Corporation reported significant financial improvements in its latest 10-Q filing for the six months ending June 30, 2026, showcasing a total revenue of $1.3 million, a substantial increase from $281,312 in the same period last year. The company's net income for the first half of 2026 was $475,450, a stark contrast to a net loss of $145,888 in the prior year. This turnaround is attributed primarily to a surge in revenue from OEM services, which accounted for the entirety of the revenue in 2026, compared to a smaller contribution in 2025.

The financial performance reflects a strategic pivot towards OEM services, which has led to a 362% increase in revenue compared to the previous year. The cost of revenues also rose significantly, from $92,080 to $505,634, primarily due to the increased volume of OEM service orders. Despite the rise in costs, the gross profit margin remained relatively strong, with gross profits reaching $789,614, up from $189,232 in the previous year. Operating expenses decreased slightly, indicating improved operational efficiency.

In terms of strategic developments, Bio Essence made a notable acquisition of the MediFlow AI software, valued at $3.5 million, which was financed through the issuance of 7 million shares of common stock. This acquisition is expected to enhance the company's technological capabilities and expand its service offerings. The total number of shares outstanding increased to 53,809,000 as of June 30, 2026, reflecting the company's efforts to raise capital for growth initiatives.

Operationally, the company has seen a marked improvement in its financial position, with total assets rising to $4 million from $422,474 at the end of 2025. Current liabilities decreased significantly from $2.4 million to $1.6 million, contributing to a reduction in the working capital deficit from $2 million to $998,524. However, the company still faces challenges, including an accumulated deficit of $9.1 million and a current ratio of 0.38:1, indicating potential liquidity issues.

Looking ahead, Bio Essence plans to strengthen its sales force and enhance marketing efforts to drive revenue growth. The management is also exploring additional financing options, including public or private offerings, to support ongoing operations and strategic initiatives. While the company has reported a positive net income for the first half of 2026, management acknowledges the need for continued efforts to ensure financial stability and growth in the future.